WHO Guideline: Summary of Recommendations on Pharmaceutical Pricing Policies

How will the new WHO recommendations on pharmaceutical pricing policies affect your organization?

Multimedia
Published on:
November 2, 2020

The WHO recently launched a series of recommendations on pharmaceutical pricing policies to help countries make medicines more affordable for the global population and lessen the burden on government budgets.

Alira Health’s Nerea Blanque-Catalina, VP, Market Access & Pricing, and Luis Culla, Associate Director, Global Market Access, dive into these new recommendations and provide advice on how companies can manage the impact of these new guidelines.

For more information and to connect with the team, contact us here.

Listen to our podcast: Alira Health’s Transformation Talks

In this episode we talk about the above-mentioned updated WHO Guideline with our insight industry experts calling from around the globe, Omar Ali, Lecturer Value-Based Pricing and Outcomes Based Innovative Contracting and Former Member Adoption and Impact Panel at NICE, and Oscar Pérez Albet, Chief Business Development and Global Alliances Officer, and our Alira Health hosts  Kenny Carberry, Associate Director, Clinical Development, and NereaBlanqué-Catalina, VP, Market Access & Pricing.

WHO Guideline: Summary of Recommendations on Pharmaceutical Pricing Policies

Report Download

Related news

Pharma
Events August 30, 2021
Event: German Biotechnology Days
Join Daniela Sica, VP Business Development, Pharma and Biotech at Alira Health and Barbara Pejic, Business Development Manager at CROS NT at German Biotech Days.
Pharma
Events August 19, 2021
Event: IPLS Autumn Workshop & Networking Reception
Join Daniela Sica at IPLS Autumn Workshop & Networking Reception.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Due Diligence Pharma
News July 21, 2021
Alira Health Announces its Role as Strategic Advisor to Naxicap
Alira Health is proud to announce its role as strategic advisor to Naxicap in the equity investment in Ceres Pharma Bv.
Digital Health Market Access
Publications April 20, 2021
Health Economics Evaluation and Value Proposition for an Antimicrobial Medical Device in the U.S. Market
A health economics evaluation assists companies during product development to better understand the product's impact across the ecosystem and position it appropriately.
Due Diligence MedTech Patient Engagement Pharma
Multimedia April 12, 2021
Evolution of the Drug Delivery Systems Industry and its Increasing Role in Driving Patient Outcomes
In the third episode, Amira Ghozali, Aptar Pharma, Kenny Carberry, and Aude Ouensanga, discuss the evolution of the DDS industry, its relationship with Pharma, and its increasing role(...)
M&A MedTech Pharma
News April 12, 2021
Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.